Preventive health care, 2001 update: Use of varicella vaccine in healthy populations
Prepared by S.A. Skull, MBBS, FRACP, FAFPHM, MAppEpid, E.E.L. Wang, MCDM, FRCP(C), with the Canadian Task Force on Preventive Health Care
These recommendations were finalized by the Task Force in June 1999.
| MANEUVER | EFFECTIVENESS | LEVEL OF EVIDENCE <REF> | RECOMMENDATION |
| Immunization of 12-15 month old children with varicella vaccine | Effective in preventing varicella infection and secondary cases in household contacts |
Randomized
control trials (I)
<35,
36, 43-45> Prospective cohort studies (II-2) <46-48, 50-56> |
Good evidence to include in routine health care (A)* |
| Catch-up immunization of children to 12 years with varicella vaccine | Effective in preventing varicella infection and secondary cases in household contacts | Randomized
control trials (I)
<35,
36, 43-45 Prospective cohort studies (II-2) <46-49, 51-56, 78> |
Good evidence to include in routine health care (A) |
| Immunization of susceptible adolescents with varicella vaccine | Effective in preventing varicella infection and secondary cases in household contacts | Prospective cohort studies (II-2) <51-53, 60> | Fair evidence to include in routine health care (B) |
| Immunization of susceptible adults with varicella vaccine | Effective
in preventing varicella infection and secondary cases in household
contacts |
Controlled
trials (II-1)
<57 Prospective cohort studies (II-2) <58-60> |
Fair evidence to include in routine health care (B) |
*
Good evidence also exists for simultaneous administration with MMR vaccine at
separate sites.
Link to Recommendation Statement of this review
Link to Full Technical Report (in pdf)
Link to Structured Abstract of this review
Link to Selected References list of this review
Reprinted in modified format by the Canadian
Task Force on Preventive Health Care
with permission.
Original Copyright
© 2000 Canadian Medical Association.
For any technical issues please contact: webmaster@ctfphc.org
Last modified: September 16, 2003
